IL305572A - KRAS inhibitors - Google Patents
KRAS inhibitorsInfo
- Publication number
- IL305572A IL305572A IL305572A IL30557223A IL305572A IL 305572 A IL305572 A IL 305572A IL 305572 A IL305572 A IL 305572A IL 30557223 A IL30557223 A IL 30557223A IL 305572 A IL305572 A IL 305572A
- Authority
- IL
- Israel
- Prior art keywords
- methoxy
- diazabicyclo
- fluoro
- nonan
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160436P | 2021-03-12 | 2021-03-12 | |
| US202163288965P | 2021-12-13 | 2021-12-13 | |
| PCT/US2022/020230 WO2022192790A1 (en) | 2021-03-12 | 2022-03-14 | Kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305572A true IL305572A (en) | 2023-10-01 |
Family
ID=81074021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305572A IL305572A (en) | 2021-03-12 | 2022-03-14 | KRAS inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240217982A1 (https=) |
| EP (1) | EP4305037B1 (https=) |
| JP (1) | JP2024510207A (https=) |
| KR (1) | KR20230169968A (https=) |
| AU (1) | AU2022232460A1 (https=) |
| BR (1) | BR112023017661A2 (https=) |
| CA (1) | CA3210383A1 (https=) |
| ES (1) | ES3014892T3 (https=) |
| IL (1) | IL305572A (https=) |
| MX (1) | MX2023010429A (https=) |
| WO (1) | WO2022192790A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN118344386A (zh) * | 2023-01-13 | 2024-07-16 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| WO2023179629A1 (zh) * | 2022-03-22 | 2023-09-28 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| MX2024011631A (es) * | 2022-03-25 | 2024-09-30 | Lilly Co Eli | Inhibidores de kras. |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202416976A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商南京明德新藥研發有限公司 | 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物 |
| WO2024061365A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都奥睿药业有限公司 | 嘧啶并环类化合物及其制备方法与用途 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| JP2025536369A (ja) | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2021031952A1 (zh) * | 2019-08-16 | 2021-02-25 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| EP4291199A4 (en) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
-
2022
- 2022-03-14 JP JP2023555534A patent/JP2024510207A/ja active Pending
- 2022-03-14 WO PCT/US2022/020230 patent/WO2022192790A1/en not_active Ceased
- 2022-03-14 CA CA3210383A patent/CA3210383A1/en active Pending
- 2022-03-14 IL IL305572A patent/IL305572A/en unknown
- 2022-03-14 AU AU2022232460A patent/AU2022232460A1/en active Pending
- 2022-03-14 BR BR112023017661A patent/BR112023017661A2/pt unknown
- 2022-03-14 MX MX2023010429A patent/MX2023010429A/es unknown
- 2022-03-14 EP EP22714316.1A patent/EP4305037B1/en active Active
- 2022-03-14 KR KR1020237034230A patent/KR20230169968A/ko active Pending
- 2022-03-14 ES ES22714316T patent/ES3014892T3/es active Active
- 2022-03-14 US US18/550,237 patent/US20240217982A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024510207A (ja) | 2024-03-06 |
| BR112023017661A2 (pt) | 2023-12-05 |
| EP4305037B1 (en) | 2025-02-26 |
| MX2023010429A (es) | 2023-09-12 |
| WO2022192790A1 (en) | 2022-09-15 |
| EP4305037A1 (en) | 2024-01-17 |
| US20240217982A1 (en) | 2024-07-04 |
| ES3014892T3 (en) | 2025-04-28 |
| CA3210383A1 (en) | 2022-09-15 |
| AU2022232460A1 (en) | 2023-09-14 |
| KR20230169968A (ko) | 2023-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL305572A (en) | KRAS inhibitors | |
| ES3013592T3 (en) | Kras g12d inhibitors | |
| TWI912127B (zh) | KRas G12D抑制劑 | |
| WO2024054926A1 (en) | Kras g12d inhibitors | |
| KR20250048078A (ko) | Kras 억제제 | |
| CA3224284A1 (en) | Kras g12d inhibitor and use thereof | |
| KR20250048579A (ko) | Kras 억제제 | |
| AU2024305928A1 (en) | Kras inhibitors | |
| JP2025519584A (ja) | Ｋｒａｓ阻害剤としてのピリド［４，３－ｄ］ピリミジン誘導体 | |
| TW202346295A (zh) | 作為iap拮抗劑的三環雜環化合物 | |
| WO2025166274A1 (en) | Tricyclic guanidino compounds as prmt5 inhibitors | |
| WO2025043225A2 (en) | Degraders of cyclin-dependent kinase 2 | |
| TW202513069A (zh) | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 | |
| CN117177976A (zh) | Kras抑制剂 | |
| CN117242074A (zh) | Kras g12d抑制剂 | |
| EA050560B1 (ru) | Ингибиторы kras | |
| EA050518B1 (ru) | Ингибиторы kras g12d | |
| WO2025194599A1 (en) | Heterocycle ulk1/2 inhibitors and methods of use thereof | |
| TW202547467A (zh) | 雜芳基衍生化合物及其用途 |